MX2021010477A - Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. - Google Patents

Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.

Info

Publication number
MX2021010477A
MX2021010477A MX2021010477A MX2021010477A MX2021010477A MX 2021010477 A MX2021010477 A MX 2021010477A MX 2021010477 A MX2021010477 A MX 2021010477A MX 2021010477 A MX2021010477 A MX 2021010477A MX 2021010477 A MX2021010477 A MX 2021010477A
Authority
MX
Mexico
Prior art keywords
conjugates
cancer
azetidobenzodiazepine
dimers
treatment
Prior art date
Application number
MX2021010477A
Other languages
English (en)
Inventor
Philip Wilson Howard
Thais Cailleau
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1903541.9A external-priority patent/GB201903541D0/en
Priority claimed from GBGB2000121.0A external-priority patent/GB202000121D0/en
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2021010477A publication Critical patent/MX2021010477A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Un compuesto de la fórmula IV: (ver Fórmula) así como enlazadores de fármaco y conjugados que comprenden este compuesto y el uso de los conjugados e 5 n el tratamiento de cáncer.
MX2021010477A 2019-03-15 2020-03-13 Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. MX2021010477A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1903541.9A GB201903541D0 (en) 2019-03-15 2019-03-15 Compounds and conjugates
GBGB2000121.0A GB202000121D0 (en) 2020-01-06 2020-01-06 Compounds and conjugates
PCT/EP2020/056761 WO2020187721A1 (en) 2019-03-15 2020-03-13 Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021010477A true MX2021010477A (es) 2021-10-01

Family

ID=69845376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010477A MX2021010477A (es) 2019-03-15 2020-03-13 Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.

Country Status (12)

Country Link
US (1) US20220160881A1 (es)
EP (1) EP3938372B1 (es)
JP (1) JP2022524880A (es)
KR (1) KR20210139270A (es)
CN (1) CN113631560A (es)
AU (1) AU2020242747A1 (es)
CA (1) CA3130174A1 (es)
IL (1) IL286326A (es)
MX (1) MX2021010477A (es)
SG (1) SG11202108900WA (es)
WO (1) WO2020187721A1 (es)
ZA (1) ZA202105931B (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE240334T1 (de) 1998-08-27 2003-05-15 Spirogen Ltd Pyrrolobenzodiazepine
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
AU2005219626B2 (en) 2004-03-01 2010-11-18 Medimmune Limited 11-hydroxy-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of C2 substituted pyrrolobenzodiazepines
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
DK1879901T3 (da) 2005-04-21 2010-05-03 Spirogen Ltd Pyrrolobenzodiazepiner
EP1813614B1 (en) 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
RS58921B1 (sr) 2012-10-12 2019-08-30 Medimmune Ltd Pirolobenzodiazepini i njihovi konjugati
LT2906251T (lt) * 2012-10-12 2017-12-11 Adc Therapeutics Sa Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3313854A1 (en) 2015-06-23 2018-05-02 Bristol-Myers Squibb Company Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
MA46789A (fr) 2016-11-10 2019-09-18 Medimmune Llc Molécules de liaison spécifiques d'asct2 et leurs utilisations
PT3612537T (pt) * 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina

Also Published As

Publication number Publication date
ZA202105931B (en) 2024-01-31
WO2020187721A1 (en) 2020-09-24
CN113631560A (zh) 2021-11-09
CA3130174A1 (en) 2020-09-24
JP2022524880A (ja) 2022-05-10
SG11202108900WA (en) 2021-09-29
EP3938372A1 (en) 2022-01-19
KR20210139270A (ko) 2021-11-22
IL286326A (en) 2021-10-31
EP3938372B1 (en) 2023-10-25
US20220160881A1 (en) 2022-05-26
AU2020242747A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
CR20200140A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MY192888A (en) Dna alkylating agents
TW201613887A (en) Antiproliferative compounds and methods of use thereof
NZ629456A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
NZ631082A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
TN2019000210A1 (en) Antitumoral compounds
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX2018010993A (es) Derivados de icariina e icaritina.
MX2022001004A (es) Inhibidores de enzimas.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2022008099A (es) Tratamiento para el cancer con inhibidores de cdk12/13.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
AU2017394032A8 (en) Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
WO2018146390A8 (fr) Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer